Financials
- Financial year
- 2025
- Total assets
- €516
- Loss
- -€62,266
- Solvency
- -19760.6%
Total assets▼ 98.7%
Net result
20222025
EQUIVITA GENETICS
InactiveOverview
Activity
“Het uitvoeren en coördineren van klinische studies in de meest ruime zin van het…” (deed in Dutch)
From the articles, 13 activitiesNo NACE code in the KBO yet
Size
≈ €160,000turnover 2025, estimated
- Staff
- 0.7 FTE
- Equity
- -€102,010
- Loss
- -€62,266
Turnover estimated from the gross margin
Financial health
Inactive: no score
Structure
- Largest shareholder
- CUR@DOMUM · 33.33%
- VERTESSEN Viktor-Jan Paul SylvieDirector
2 of 3 deeds summarised
Signalsraises riskNegative equityneutralLatest accounts filed on timeShow the evidence
Signals
Two signals.
raises riskneutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
22232425
2022 to 2025 · latest year -€102,010
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-06-2026, 35 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
35 days early
2024
29 days late
2023
26 days late
2022
18 days early
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 4 accounts on average 1 day after the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (1)
- Resignations & appointments · End &…Resignations: VERTESSEN Viktor-Jan, VERTESSEN Charlotte…
- Annual accounts filedfinancial year 2025 · micro…
- Annual accounts filedfinancial year 2024 · micro…
Key points
By topic
Board & ownership
- Board
- 1 member
- Largest shareholder
- CUR@DOMUM · 33.33%
- VERTESSEN Viktor-Jan Paul SylvieDirector
Network & group
- Connected companies
- 2
Timeline
- Events
- 7
- Since
- 2023
- 26-08-2024Annual accounts filed
- 31-12-2023Weakest financial year
- 13-07-2023Annual accounts filed
Company details
- Legal form
- Private limited company
- Year ends
- 31-12
- Peppol
- Still in the Peppol directory
Articles of association
- Provisions read
- 16
- Who signs
- Two directors jointly
- Annual meeting
- Third Thursday of June at 20:00
- Purpose
- “Het uitvoeren en coördineren van klinische studies in de meest ruime zin van het woord…” (deed in Dutch)
Key facts about EQUIVITA GENETICS
- What is the company number of EQUIVITA GENETICS?
- 0772.385.165. In Belgium the VAT number is the company number with BE in front: BE 0772.385.165.
- What is the legal form of EQUIVITA GENETICS?
- Private limited company (BV).
- Is EQUIVITA GENETICS still active?
- No. EQUIVITA GENETICS is inactive in the KBO register.Company details
- How many employees did EQUIVITA GENETICS have?
- On average 0.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of EQUIVITA GENETICS?
- Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
- Is EQUIVITA GENETICS profitable?
- In financial year 2025, EQUIVITA GENETICS made a loss of €62,266.
- Where can I find the annual accounts of EQUIVITA GENETICS?
- EQUIVITA GENETICS filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
Companies related to EQUIVITA GENETICS
Shareholders
- CUR@DOMUM33.33%
Go further with this company
What became of the directors' other companies?Supplier due diligence Who ran this company, and where was it based, on a given date before it ended?Company as of a date How is this company connected to another party?Network investigator
Investigating this company? Keep it with today's facts in a case file.